Emergent Biosolutions INC 8-K filings

Emergent BioSolutions' ACAM2000 vaccine has received FDA approval for expanded use to include the prevention of mpox in high-risk individuals, amidst a global outbreak.

Emergent BioSolutions has finalized the sale of its Baltimore-Camden drug product facility to Bora Pharmaceuticals for approximately $30 million, marking a step in its multi-year turnaround plan.

Emergent BioSolutions reported second quarter revenues above prior guidance, while still experiencing a net loss, as the company continues its strategic restructuring efforts.

Emergent BioSolutions has completed the sale of its RSDL (Reactive Skin Decontamination Lotion) kit to SERB Pharmaceuticals for $75 million, plus a potential $5 million milestone payment.

Emergent BioSolutions announces the resignation of Executive Vice President Jennifer Fox, effective August 16, 2024, as she pursues an opportunity outside the company.

Emergent BioSolutions has granted a one-time equity award of 15,000 restricted stock units to Executive Vice President Jennifer Fox in recognition of her contributions to recent strategic initiatives.

Emergent BioSolutions has reached a settlement with Janssen Pharmaceuticals, resolving all claims related to a manufacturing agreement for a COVID-19 vaccine and securing a $50 million payment.

Emergent BioSolutions has been awarded over $250 million in contract modifications to supply the U.S. government with critical medical countermeasures for anthrax, smallpox, and botulism.

Emergent BioSolutions has agreed to sell its Baltimore-Camden drug product facility to Bora Pharmaceuticals for approximately $30 million, with around 350 employees expected to transfer to Bora.

Emergent BioSolutions' stockholders approved an amendment to the company's stock incentive plan, increasing the number of shares reserved for issuance and modifying how full-value awards are counted, at their 2024 annual meeting.

Emergent BioSolutions reported a strong first quarter of 2024 with significant revenue growth and a revised government contract, alongside updated financial guidance.

Emergent BioSolutions is implementing a restructuring plan involving workforce reductions and facility closures to achieve $80 million in annualized cost savings.

Emergent BioSolutions has amended its credit agreement, reducing its revolving credit facility and increasing interest rates, while also requiring a capital raise of at least $85 million by July 31, 2024.

Emergent BioSolutions has amended its key employee retention agreements, providing additional retention bonuses to four named executive officers.

Emergent BioSolutions entered a forbearance agreement with lenders, reported a net loss for Q4 and full year 2023, and provided financial guidance for 2024.

Emergent BioSolutions has appointed Joseph C. Papa as its new President and CEO, effective February 21, 2024, succeeding interim CEO Haywood Miller.

Emergent BioSolutions has been awarded a contract with a maximum value of $235.8 million to supply its BioThrax anthrax vaccine to the U.S. Department of Defense.